Video

Paul Christo, MD: Addressing Opioid Addiction during the COVID-19 Pandemic

Author(s):

Paul Christo, MD, discusses opioid addiction during the pandemic, the role of the clinician, and offers a hopeful outlook for the future.

For many people, the coronavirus disease 2019 (COVID-19) pandemic lockdown measures have led to increased feelings of isolation, stress, and depression. As a result, many have turned to opioid use, thus leading to elevated instances of related overdoses and deaths.

With these initial restrictions on access healthcare services came the rise of and reliance on telemedicine.

In an interview with HCPLive®, Paul Christo, MD, Professor of Anesthesiology and Critical Care, Medicine, Johns Hopkins School of Medicine, explained that telemedicine and “tele-mental health” services have become increasingly useful for those in need.

“As a practitioner, I think that it’s important to advocate to patients that they have connections that are available online via telehealth services,” he said.

He went on to underscore this relationship between addiction and a lack of communication and loss of control. Thus, he believed that the use of tele-mental health services can help such individuals to address these concerns.

Further, Christo mentioned certain agonist therapies, such as methadone and buprenorphine, have become easier to access and acquire through mobile / remote means. These medications are critical to maintaining sobriety and preventing relapse.

Another important medication is naloxone (Narcan), which is an opioid-reversal agent. And yet, there is little visibility of it across the population. According to Christo, there is certainly potential to improve communication related to the importance of the drug for individuals who overuse opioids.

In reference to the ongoing COVID-19 pandemic’s effect on the opioid crisis, he nonetheless offered encouraging words.

“I think there’s hope, because of what we’ve learned from the initial stages of COVID-19, when everything was closed,” he said.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
© 2024 MJH Life Sciences

All rights reserved.